Abstract
The cellular network and its environment govern cell and organism behavior and are fundamental to the comprehension of function, misfunction and drug discovery. Over the last few years, drugs were observed to often bind to more than one target; thus, polypharmacology approaches can be advantageous, complementing the “one drug - one target” strategy. Targeting drug discovery from the systems biology standpoint can help in studies of network effects of mono- and poly-pharmacology. In this mini-review, we provide an overview of the usefulness of network description and tools for mono- and poly-pharmacology, and the ways through which protein interactions can help single- and multi-target drug discovery efforts. We further describe how, when combined with experimental data, modeled structural networks which can predict which proteins interact and provide the structures of their interfaces, can model the cellular pathways, and suggest which specific pathways are likely to be affected. Such structural networks may facilitate structure-based drug design; forecast side effects of drugs; and suggest how the effects of drug binding can propagate in multi-molecular complexes and pathways.
Keywords: Poly-pharmacology, network pharmacology, protein-protein interaction inhibitors, systems biology, protein-protein interfaces, modeling.
Current Pharmaceutical Design
Title:Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Volume: 20 Issue: 8
Author(s): H. Billur Engin, Attila Gursoy, Ruth Nussinov and Ozlem Keskin
Affiliation:
Keywords: Poly-pharmacology, network pharmacology, protein-protein interaction inhibitors, systems biology, protein-protein interfaces, modeling.
Abstract: The cellular network and its environment govern cell and organism behavior and are fundamental to the comprehension of function, misfunction and drug discovery. Over the last few years, drugs were observed to often bind to more than one target; thus, polypharmacology approaches can be advantageous, complementing the “one drug - one target” strategy. Targeting drug discovery from the systems biology standpoint can help in studies of network effects of mono- and poly-pharmacology. In this mini-review, we provide an overview of the usefulness of network description and tools for mono- and poly-pharmacology, and the ways through which protein interactions can help single- and multi-target drug discovery efforts. We further describe how, when combined with experimental data, modeled structural networks which can predict which proteins interact and provide the structures of their interfaces, can model the cellular pathways, and suggest which specific pathways are likely to be affected. Such structural networks may facilitate structure-based drug design; forecast side effects of drugs; and suggest how the effects of drug binding can propagate in multi-molecular complexes and pathways.
Export Options
About this article
Cite this article as:
Engin Billur H., Gursoy Attila, Nussinov Ruth and Keskin Ozlem, Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View, Current Pharmaceutical Design 2014; 20 (8) . https://dx.doi.org/10.2174/13816128113199990066
DOI https://dx.doi.org/10.2174/13816128113199990066 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry in vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)
Recent Patents on Anti-Cancer Drug Discovery Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy Regulatory Cross Talks of Bone Cells, Hematopoietic Stem Cells and the Nervous System Maintain Hematopoiesis
Inflammation & Allergy - Drug Targets (Discontinued) The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy